AI assistant
RACURA ONCOLOGY LTD — Call Transcript 2017
Mar 9, 2017
65658_rns_2017-03-09_a93e24c1-673d-4696-83cf-f246aad5821d.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [180 x 91] intentionally omitted <==
ASX RELEASE
RACE ONCOLOGY INVESTOR CONFERENCE CALL
10 March 2017: Specialty pharmaceutical company, Race Oncology Ltd (ASX: RAC) is pleased to advise that the Company will host a conference call for investors on Thursday, 16 March 2017 at the times listed below.
Race CEO Peter Molloy and Chairman Dr Bill Garner will be on the call to answer shareholder questions. The conference call will include a brief introduction from the CEO on the Company and its progress, with the remainder of the session dedicated to shareholders’ questions. Investors may wish to review the Company’s updated Investor Presentation released 9 March 2017, as this will be referenced during the conference call.
Questions may be submitted ahead of the conference call via email to: [email protected]
Conference call details:
Date: Thursday, 16 March 2017
Time: 2:00pm Sydney time (AEDT) / 11:00am Perth time (AWST) – participants are requested to dial in 5 minutes prior to the start time
Conference ID: 8392 8573
Dial-in numbers:
Domestic participants can dial either of the numbers below to join the call.
Toll Free: 1800 123 296 or Toll: +61 2 8038 5221
International toll-free numbers are listed below. For countries not listed below, the Australian Toll number can be dialled.
| Canada: | 1855 5616 766 | New Zealand: | 0800 452 782 |
|---|---|---|---|
| China: | 4001 203 085 / 8008 702 411 Singapore: | 800 616 2288 | |
| Hong Kong: | 800 908 865 | United Kingdom: | 0808 234 0757 |
| India: | 1800 3010 6141 | United States: | 1855 293 1544 |
| Japan: | 0120 477 087 |
For shareholders not able to listen in at the time of the conference call, an archived copy of the call will be available shortly after via http://www.openbriefing.com/OB/2474.aspx
Race Oncology Limited, ABN 61 149 318 749 Level 2, 50 Kings Park Road, West Perth WA 6005 www.raceoncology.com
About Race Oncology
Race Oncology Limited is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. Visit raceoncology.com for more information.
For more information, contact:
Peter Molloy T: +61 (0) 3 9097 1656 Managing Director E: [email protected]
Investor Relations
F T I Consulting
T: +61 (0)8 9485 8888